EP4242304A3 - Methods and reagents for analyzing protein-protein interfaces - Google Patents

Methods and reagents for analyzing protein-protein interfaces Download PDF

Info

Publication number
EP4242304A3
EP4242304A3 EP23172763.7A EP23172763A EP4242304A3 EP 4242304 A3 EP4242304 A3 EP 4242304A3 EP 23172763 A EP23172763 A EP 23172763A EP 4242304 A3 EP4242304 A3 EP 4242304A3
Authority
EP
European Patent Office
Prior art keywords
protein
interfaces
reagents
analyzing
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23172763.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4242304A2 (en
Inventor
Gregory L. Verdine
M. James Nichols
Sharon A. Townson
Uddhav Kumar Shigdel
Seung-Joo Lee
Dylan T. Stilles
Neville J. Anthony
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revolution Medicines Inc
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of EP4242304A2 publication Critical patent/EP4242304A2/en
Publication of EP4242304A3 publication Critical patent/EP4242304A3/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G01N2410/08—Cyclosporins and related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP23172763.7A 2015-10-01 2016-09-30 Methods and reagents for analyzing protein-protein interfaces Pending EP4242304A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235896P 2015-10-01 2015-10-01
EP16852685.3A EP3355930A4 (en) 2015-10-01 2016-09-30 METHOD AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES
PCT/US2016/054691 WO2017059207A1 (en) 2015-10-01 2016-09-30 Methods and reagents for analyzing protein-protein interfaces

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP16852685.3A Division EP3355930A4 (en) 2015-10-01 2016-09-30 METHOD AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES

Publications (2)

Publication Number Publication Date
EP4242304A2 EP4242304A2 (en) 2023-09-13
EP4242304A3 true EP4242304A3 (en) 2024-02-07

Family

ID=58427956

Family Applications (2)

Application Number Title Priority Date Filing Date
EP23172763.7A Pending EP4242304A3 (en) 2015-10-01 2016-09-30 Methods and reagents for analyzing protein-protein interfaces
EP16852685.3A Withdrawn EP3355930A4 (en) 2015-10-01 2016-09-30 METHOD AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP16852685.3A Withdrawn EP3355930A4 (en) 2015-10-01 2016-09-30 METHOD AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES

Country Status (6)

Country Link
US (5) US9989535B2 (https=)
EP (2) EP4242304A3 (https=)
JP (2) JP7411326B2 (https=)
AU (3) AU2016329064B2 (https=)
CA (1) CA3000822A1 (https=)
WO (1) WO2017059207A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
US10533016B2 (en) 2015-01-09 2020-01-14 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
WO2017059207A1 (en) 2015-10-01 2017-04-06 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
US10774110B2 (en) 2016-02-04 2020-09-15 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
CA3013783A1 (en) 2016-02-04 2017-08-10 The Johns Hopkins University Rapaglutins, novel inhibitors of glut and use thereof
CA3020594A1 (en) 2016-04-12 2017-10-19 Warp Drive Bio, Inc. Compositions and methods for the production of compounds
KR102598895B1 (ko) 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
MX2019008696A (es) 2017-01-23 2019-09-13 Revolution Medicines Inc Compuestos de piridina como inhibidores de shp2 alostericos.
KR20240093922A (ko) * 2017-04-05 2024-06-24 레볼루션 메디슨즈, 인크. 단백질-단백질 계면을 분석하기 위한 방법 및 시약
AU2018248417A1 (en) * 2017-04-05 2019-11-14 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
MX2020003579A (es) 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
US11802132B2 (en) * 2018-02-23 2023-10-31 Dana-Farber Cancer Institute, Inc. Small molecules for inducing selective protein degradation and uses thereof
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
US20250388598A1 (en) * 2019-11-04 2025-12-25 Revolution Medicines, Inc. Ras inhibitors
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
EP4055365B1 (en) * 2019-11-08 2026-01-21 NanoTemper Technologies GmbH Characterization of particles in solution
CN111118046B (zh) * 2020-01-16 2022-02-22 中国人民解放军军事科学院军事医学研究院 一种能够调控MSCs成脂肪分化能力的基因及其衍生产品
GB202007106D0 (en) * 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN119661684B (zh) * 2024-10-21 2025-11-25 山东大学 一种高抗炎活性的脂联素突变体及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137877A (en) * 1990-05-14 1992-08-11 Bristol-Myers Squibb Bifunctional linking compounds, conjugates and methods for their production

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE92501T1 (de) 1984-10-04 1993-08-15 Sandoz Ag Monoklonale antikoerper gegen zyklosporine.
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
DK0393934T3 (da) 1989-04-15 1994-11-21 Nippon Chemiphar Co Nye peptider samt antidemensmidler indeholdende disse peptider
DK0562853T3 (da) 1992-03-27 1996-07-01 American Home Prod 29-Demethoxyrapamycin til fremkaldelse af immunsuppression
ES2164713T3 (es) 1993-09-20 2002-03-01 Univ Leland Stanford Junior Produccion recombinante de nuevos poliquetidos.
IL112873A (en) 1994-03-08 2005-03-20 Wyeth Corp Rapamycin-fkbp12 binding proteins, their isolation and their use
GB9410142D0 (en) 1994-05-20 1994-07-06 Univ Warwick Carbapenems
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
SE9603465D0 (sv) 1996-09-23 1996-09-23 Astra Ab New compounds
US6902913B2 (en) 1997-04-30 2005-06-07 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6153383A (en) 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
ES2347027T3 (es) 1998-05-22 2010-10-22 The Board Of Trustees Of The Leland Stanford Junior University Moleculas bifuncionales y terapias basadas en las mismas.
NZ510819A (en) 1998-10-02 2004-03-26 Kosan Biosciences Inc Polyketide synthase enzymes and recombinant DNA constructs therefor
US6686454B1 (en) * 1998-10-09 2004-02-03 Isotechnika, Inc. Antibodies to specific regions of cyclosporine related compounds
GB9927191D0 (en) 1999-11-17 2000-01-12 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
US7220552B1 (en) * 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
AU1776501A (en) 1999-11-19 2001-05-30 Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
TR200200767T1 (tr) 2000-05-23 2002-09-23 Vertex Pharmaceuticals Incorporated Kaspaz engelleyiciler ve kullanımları
US7176037B2 (en) 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US20030153053A1 (en) 2001-08-06 2003-08-14 Ralph Reid Methods for altering polyketide synthase genes
US6809077B2 (en) * 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
WO2004041279A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
US7012065B2 (en) * 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
US8653238B2 (en) * 2006-02-27 2014-02-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for transport of molecules with enhanced release properties across biological barriers
US20070203168A1 (en) 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
US7601852B2 (en) 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
GB0805363D0 (en) 2008-03-20 2008-04-30 Sinvent As Novel NRPS-PKS gene cluster and its manipulation and utility
WO2010031185A1 (en) 2008-09-19 2010-03-25 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
EP2342335B1 (en) 2008-09-24 2015-09-16 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Novel gene cluster
WO2010088573A1 (en) 2009-01-30 2010-08-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c infection
JP2012532929A (ja) * 2009-07-13 2012-12-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二機能性のステープリングされたポリペプチドおよびそれらの使用
EP2456777A2 (en) 2009-07-24 2012-05-30 Université Henri Poincaré - Nancy 1 Stambomycin and derivatives, their production and their use as drugs
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
US20120208720A1 (en) 2009-10-22 2012-08-16 Kenji Kashiwagi Rapid display method in translational synthesis of peptide
EP2646440A4 (en) 2010-11-30 2014-06-18 Univ Johns Hopkins CYCLIC HYBRID LIBRARIES AND SCREENS FOR THIS
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
AU2012257513B2 (en) 2011-05-19 2017-05-11 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
WO2012174489A2 (en) 2011-06-15 2012-12-20 The Ohio State University Small molecule composite surfaces as inhibitors of protein-protein interactions
DE102011111991A1 (de) * 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
WO2013052393A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
PL2872157T3 (pl) 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
US10131682B2 (en) * 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
EP2806274A1 (en) 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
US10233431B2 (en) 2014-02-26 2019-03-19 The Regents Of The University Of California Producing 3-hydroxycarboxylic acid and ketone using polyketide synthases
US20170067894A1 (en) 2014-03-03 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method and device for detection of pseudomonas aeruginosa
US10533016B2 (en) 2015-01-09 2020-01-14 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
TW201629069A (zh) 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
US10077289B2 (en) * 2015-03-31 2018-09-18 Allergan, Inc. Cyclosporins modified on the MeBmt sidechain by heterocyclic rings
WO2017059207A1 (en) 2015-10-01 2017-04-06 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
JP2020501519A (ja) 2016-10-28 2020-01-23 ギンゴー バイオワークス， インコーポレイテッド 化合物の生産のための組成物および方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137877A (en) * 1990-05-14 1992-08-11 Bristol-Myers Squibb Bifunctional linking compounds, conjugates and methods for their production
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PFLANZ G ET AL: "Induction and rapid screening of monoclonal antibodies against cyclosporin A", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 18, no. 4, 1 August 1988 (1988-08-01), pages 241 - 245, XP023691993, ISSN: 0165-2478, [retrieved on 19880801], DOI: 10.1016/0165-2478(88)90169-1 *
RICHARD SEDRANI ET AL: "Sanglifehrin-Cyclophilin Interaction: Degradation Work, Synthetic Macrocyclic Analogues, X-ray Crystal Structure, and Binding Data", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, vol. 125, 2 April 2003 (2003-04-02), pages 3849 - 3859, XP002632408, ISSN: 0002-7863, [retrieved on 20030306], DOI: 10.1021/JA021327Y *
WHITE JAMES D. ET AL: "Synthesis of the Tripeptide Domain of Sanglifehrins Using Asymmetric Phase-Transfer Catalysis", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 78, no. 6, 22 February 2013 (2013-02-22), pages 2757 - 2762, XP055981139, ISSN: 0022-3263, DOI: 10.1021/jo3027214 *
ZHICAI YANG ET AL: "Novel Oxidation of Cyclosporin A: Preparation of Cyclosporin Methyl Vinyl Ketone (Cs-MVK)", SYNLETT, vol. 2009, no. 18, 2 October 2009 (2009-10-02), DE, pages 2935 - 2938, XP055259220, ISSN: 0936-5214, DOI: 10.1055/s-0029-1218011 *

Also Published As

Publication number Publication date
CA3000822A1 (en) 2017-04-06
US9989535B2 (en) 2018-06-05
US20170097359A1 (en) 2017-04-06
JP7411326B2 (ja) 2024-01-11
JP2019501863A (ja) 2019-01-24
AU2016329064A1 (en) 2018-04-26
EP4242304A2 (en) 2023-09-13
WO2017059207A8 (en) 2018-01-11
AU2024200321A1 (en) 2024-02-08
EP3355930A1 (en) 2018-08-08
AU2016329064B2 (en) 2023-10-19
US10466249B2 (en) 2019-11-05
WO2017059207A1 (en) 2017-04-06
US20180252726A1 (en) 2018-09-06
EP3355930A4 (en) 2019-03-06
US20210405060A1 (en) 2021-12-30
US10948495B2 (en) 2021-03-16
JP2023052201A (ja) 2023-04-11
AU2026201288A1 (en) 2026-03-12
US20250085291A1 (en) 2025-03-13
JP7812813B2 (ja) 2026-02-10
US20180259535A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
EP4242304A3 (en) Methods and reagents for analyzing protein-protein interfaces
MX2025014195A (es) Metodos y reactivos para analizar las interfaces entre proteinas
EP4365597A3 (en) Methods of assaying proteins
EP4567127A3 (en) Methods for determining a location of a biological analyte in a biological sample
EP4010456A4 (en) SYSTEMS AND METHODS FOR SAMPLE PREPARATION, DATA GENERATION AND PROTEIN CORONA ANALYSIS
WO2021097365A3 (en) Antigen-binding proteins targeting shared neoantigens
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
EP3987054A4 (en) SAMPLE ANALYSIS SYSTEMS
AU2018318303A1 (en) Antigen-binding proteins targeting shared antigens
EP4442706A3 (en) Canine antibody libraries
ZA202001218B (en) Systems and methods for real time preparation of a polypeptide sample for analysis with mass spectrometry
WO2020239895A3 (en) Detection of colorectal cancer
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
WO2014146139A3 (en) Srm assay to indicate cancer therapy
AU2017308753B2 (en) Dual chamber reagent mixing container
MX2018012550A (es) Composiciones y metodos para la deteccion de proteinas de celulas huesped.
AU2018267843A1 (en) PD-L1 antibody pharmaceutical composition and use thereof
WO2021021964A3 (en) Methods of quantifying frataxin and frataxin fusion proteins
AU2018269892A8 (en) NMR methods and systems for the rapid detection of Candida species
EP3631414A4 (en) ASSAY SYSTEMS AND METHODS FOR PROCESSING SAMPLE ENTITIES
EP3495390A4 (en) NOVEL ANTIBODY AGAINST PROGRAMMED CELL DEATH PROTEIN (PD-1) AND USE OF IT
EP4306544A3 (en) Production of heteromultimeric proteins using mammalian cells
ZA202001214B (en) Systems and methods for performing a real-time glycan assay of a sample
AU2018279738A1 (en) Methods of enhancing development of renal organoids and methods of using the same
EP3545105A4 (en) SYSTEM, PROCEDURE AND SAMPLE CARRIERS FOR TESTING

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3355930

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C12N0009900000

Ipc: A61K0047420000

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: REVOLUTION MEDICINES, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/90 20060101ALI20230927BHEP

Ipc: A61K 38/17 20060101ALI20230927BHEP

Ipc: A61K 38/13 20060101ALI20230927BHEP

Ipc: A61K 38/12 20060101ALI20230927BHEP

Ipc: A61K 47/42 20170101AFI20230927BHEP

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/90 20060101ALI20240103BHEP

Ipc: A61K 38/17 20060101ALI20240103BHEP

Ipc: A61K 38/13 20060101ALI20240103BHEP

Ipc: A61K 38/12 20060101ALI20240103BHEP

Ipc: A61K 47/42 20170101AFI20240103BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40100567

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240807

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS